MK-677 Half-Life: Pharmacokinetics, Dosing and Washout
The human terminal plasma half-life of MK-677 (ibutamoren, also designated MK-0677) is approximately 24 hours. That single figure drives the entire dosing and washout logic: once-daily oral administration is pharmacokinetically sufficient, and plasma clearance to near-negligible levels takes roughly five days after the last dose.
Two practical rules follow directly from that number:
Once-daily dosing maintains trough concentrations above the threshold for continuous GH/IGF-1 stimulation, because each new dose arrives before the prior one has cleared.
Plasma clearance of most of the drug is reached after multiple half-lives, placing the washout window at roughly several days for plasma drug, though downstream pharmacodynamic markers such as IGF-1 can take one to two weeks to return to baseline.
Pro Tip: Steady state is reached in approximately 3–5 days of daily dosing. Blood samples collected before that window reflect single-dose kinetics, not the trough concentrations that govern sustained GH/IGF-1 elevation. For PK/PD study design, always confirm sampling day relative to steady-state onset.
Table of Contents
What does the evidence say about MK-677’s half-life?
How does MK-677 behave pharmacokinetically after an oral dose?
How does plasma half-life translate into GH and IGF-1 effects?
What dosing frequency and doses do clinical studies use?
How long does MK-677 stay in the system after stopping?
What safety signals does sustained GHS-R1a activation produce?
How reliable is the reported half-life, and what are the study limitations?
What should research procurement teams verify before sourcing MK-677?
Key Takeaways
A researcher’s perspective on what the half-life actually changes
Useful primary references for MK-677 pharmacokinetics
Research-grade MK-677 sourcing with verified batch documentation
What does the evidence say about MK-677’s half-life?
The approximately 24-hour terminal half-life comes from human Phase 2 pharmacokinetic studies, where steady-state plasma sampling in older adult cohorts produced the terminal elimination estimate used to justify once-daily dosing. These were controlled, multi-dose trials with serial blood draws across the dosing interval, not single-point assays.
Early animal data tell a different story. PMC review literature documents single-dose assay values in beagle dogs in the range of 4–6 hours, a figure that reflects species differences in hepatic metabolism and assay sensitivity rather than the human terminal elimination phase. That shorter value appears in preclinical pharmacology reports and occasionally circulates in secondary sources, but it does not apply to human dosing calculations.
Context Reported half-life Route Study type Source Human (steady-state) ~24 hours Oral Phase 2 multi-dose PK trial PubMed 10404019 Human (terminal, summary) ~24 hours Oral PK reference compilation Halflife-labs Beagle dog (single-dose) 4–6 hours Oral Preclinical single-dose assay PMC4121852
The 24-hour figure is the number to use for dosing frequency, washout calculations, and study scheduling. The 4–6 hour animal value is relevant only for mechanistic or cross-species pharmacology discussions.
How does MK-677 behave pharmacokinetically after an oral dose?
MK-677 is orally active, which distinguishes it from most peptide-based growth hormone secretagogues that require injection. After oral administration, the compound reaches peak plasma concentration (Tmax) within a few hours, with absorption driven by its non-peptide spiropiperidine structure that resists gastrointestinal degradation.
Key PK parameters from human studies:
Oral bioavailability is meaningful, though precise percentage estimates vary across reports and are not uniformly published in the open literature.
Tmax occurs within approximately 1–3 hours post-dose under fasted conditions.
Steady state is reached after approximately 3–5 days of once-daily dosing, at which point trough concentrations are substantially higher than after a single dose.
The terminal elimination half-life of ~24 hours governs the accumulation ratio; at steady state, trough levels are meaningfully elevated compared to single-dose troughs.
The distinction between distribution-phase and terminal-phase half-life matters here. Early post-dose concentration curves show a faster initial decline as the drug distributes into tissues, which is what shorter assay windows capture. The terminal phase, measured from later time points when distribution is complete, yields the ~24-hour figure. ChEMBL bioactivity records confirm MK-677’s target as the ghrelin receptor (GHS-R1a), a G-protein coupled receptor with central and peripheral expression, which partly explains why receptor engagement persists beyond plasma drug levels.
Pro Tip: Assay sensitivity directly affects the reported half-life. A less sensitive assay loses the drug signal earlier in the terminal phase, producing an artificially shorter estimate. When evaluating a published half-life claim, check the lower limit of quantification (LLOQ) of the assay used.
How does plasma half-life translate into GH and IGF-1 effects?
Plasma drug clearance and biological effect duration are not the same thing. MK-677 stimulates GH secretion by binding GHS-R1a in the hypothalamus and pituitary. That GH pulse then drives hepatic IGF-1 production, a downstream process with its own synthesis and clearance kinetics. IGF-1 has a plasma half-life measured in hours to days depending on binding protein status, so even after MK-677 clears, circulating IGF-1 remains elevated.
A 12-month randomized trial in healthy older adults documented sustained GH and IGF-1 elevation alongside increases in fat-free mass, confirming that continuous once-daily dosing maintains pharmacodynamic effect throughout the dosing interval. The same trial recorded a mild increase in fasting glucose and mild transient edema, both consistent with sustained GH tone rather than acute drug toxicity.
Common clinical effects that track with continuous GHS-R1a engagement:
Increased appetite (orexigenic effect), typically strongest in the first weeks and attenuating over months as central ghrelin signaling adapts.
Water retention and mild edema, driven by GH-mediated renal sodium retention.
Reduced insulin sensitivity, a known consequence of sustained GH elevation.
The pharmacodynamic timeline relative to dosing:
Hours 0–6: peak GH pulse following drug absorption.
Hours 6–24: declining plasma drug, but sustained IGF-1 elevation from hepatic production.
Days 1–7 post-cessation: IGF-1 gradually returns toward baseline as hepatic production normalizes.
Weeks 1–2 post-cessation: full IGF-1 normalization in most subjects.
What dosing frequency and doses do clinical studies use?
Once-daily oral dosing is the standard across the MK-677 clinical literature, directly supported by the ~24-hour half-life and the steady-state accumulation behavior described above. A dose arriving every 24 hours replaces drug cleared during the prior interval, maintaining trough concentrations sufficient for continuous GHS-R1a engagement.
Published trial data and peptide reference summaries consistently cite 25 mg daily as the most commonly studied dose in human trials, with some protocols using lower doses (10 mg) in dose-finding phases. Higher doses have been explored but are associated with more pronounced side effects without proportional PD benefit.
Practical dosing notes from the clinical literature:
Splitting the daily dose is not pharmacokinetically necessary given the 24-hour half-life, and no trial has demonstrated a PD advantage from twice-daily administration.
Some researchers time dosing before sleep to align the GH pulse with the natural nocturnal GH surge, potentially amplifying the combined signal.
For PK blood sampling, draws should occur at a consistent time relative to the dose (e.g., trough at 24 hours post-dose) and only after steady state is confirmed (day 4 or later).
Pro Tip: If glucose monitoring is part of the study protocol, fasting samples should be collected at the same time point relative to the dose across all subjects. GH-mediated insulin resistance shows a time-of-day pattern, and inconsistent sampling timing inflates variance in glucose and insulin data.
How long does MK-677 stay in the system after stopping?
The standard pharmacokinetic rule for plasma clearance is five half-lives, at which point approximately 97% of the drug has been eliminated. Applied to a 24-hour half-life, that calculation runs as follows:
After 1 half-life (24 hours): 50% remaining.
After 2 half-lives (48 hours): 25% remaining.
After 3 half-lives (72 hours): 12.5% remaining.
After 4 half-lives (96 hours): ~6.25% remaining.
After 5 half-lives (120 hours / ~5 days): ~3.1% remaining.
Plasma clearance to near-negligible levels therefore takes approximately five days. That is the relevant window for plasma drug washout in study designs requiring a drug-free baseline.
Key distinctions for washout planning:
Plasma drug clearance does not equal pharmacodynamic normalization.
IGF-1 levels may remain above baseline for a period after the last dose, depending on prior duration of use and individual hepatic IGF-1 production rates.
Assay detection windows depend on the LLOQ of the method used; a highly sensitive LC/MS assay may detect residual drug beyond the five-day plasma clearance estimate.
For studies requiring a clean IGF-1 baseline, a two-week washout is a more conservative and defensible interval.
Sport Integrity Australia’s ibutamoren information page notes MK-677’s long biological effect as a key regulatory concern, which aligns with the PD persistence described above.
What safety signals does sustained GHS-R1a activation produce?
The safety profile of MK-677 reflects the biology of sustained GH elevation, not direct compound toxicity. The 12-month Annals of Internal Medicine trial in healthy older adults provides the most detailed human safety dataset available in the open literature.
Principal findings from that trial and related reports:
Fasting glucose increased on average, with insulin resistance indices rising correspondingly.
Mild transient edema was reported, consistent with GH-mediated renal sodium retention.
Appetite increased, particularly in the early weeks of treatment.
No serious cardiovascular events were directly attributed to the compound in the trial period, though the cohort was selected for baseline health.
Sustained GH/IGF-1 elevation from continuous GHS-R1a agonism drives metabolic changes, primarily insulin resistance and fluid shifts, rather than direct peripheral organ toxicity. Glucose tolerance monitoring is the most clinically relevant safety measure for any research protocol using MK-677.
Recommended monitoring for research contexts:
Fasting glucose and HbA1c at baseline and at regular intervals (monthly for studies longer than 4 weeks).
Body weight and edema assessment at each study visit.
Blood pressure monitoring, given fluid retention potential.
Periodic IGF-1 measurement to confirm PD response and detect supraphysiologic elevation.
Populations requiring heightened monitoring or exclusion consideration:
Individuals with pre-diabetes or impaired fasting glucose.
Those with uncontrolled type 2 diabetes.
Subjects with active cardiovascular disease or a history of fluid-sensitive conditions.
MK-677 is not FDA-approved for any indication. Its use remains investigational, and all human research requires appropriate ethical oversight.
How reliable is the reported half-life, and what are the study limitations?
The ~24-hour terminal half-life rests on a relatively narrow evidence base. The pivotal human PK data come from Phase 2 trials conducted primarily in older adult cohorts, a population with reduced hepatic clearance capacity compared to healthy young adults. That demographic bias means the 24-hour estimate may slightly overstate the half-life in younger, metabolically active subjects.
Specific limitations in the MK-677 PK literature:
Sample sizes in the PK-focused studies are small, limiting statistical precision around the half-life estimate.
Assay methods vary across studies, and older radioimmunoassay or ELISA-based plasma quantification methods have higher LLOQs than modern LC/MS approaches, potentially truncating the terminal phase.
Most published data come from single research groups or Merck’s internal clinical program; independent replication with standardized assays is limited.
Population PK modeling across diverse age, sex, and metabolic subgroups has not been published in the open literature.
What would strengthen confidence in the current estimates: larger PK studies in healthy young adults, standardized LC/MS assay protocols across sites, and population PK modeling that accounts for age, sex, body composition, and hepatic function.
What should research procurement teams verify before sourcing MK-677?
Research-grade MK-677 procurement requires the same verification discipline applied to any small-molecule API sourced through non-pharmaceutical channels. The compound’s investigational status means there is no regulatory floor on purity or identity for research supply, making independent verification non-negotiable.
COA and testing checklist:
Purity by HPLC or UPLC: look for a reported purity of 98% or higher, with the chromatographic method and column conditions specified.
Identity confirmation: mass spectrometry (LC/MS or HRMS) confirming the molecular ion consistent with MK-677 (CID 9939050 per PubChem).
Impurity profile: residual solvents (ICH Q3C relevant solvents), process-related impurities, and any structural analogs.
Batch number and lot traceability linking the COA to the specific vial or lyophilized cake received.
Manufacturing realities to assess:
Confirm whether the supplier is an API manufacturer or a reseller. Resellers often repackage bulk API without visibility into the original synthesis batch or QC data.
Ask for the lyophilization and vialing records if purchasing finished product. Common failures at this stage include incomplete lyophilization (residual moisture), incorrect fill weight, and sterility failures in non-GMP vialing environments.
Request stability data or a retest provision. MK-677 in lyophilized form is generally stable, but storage temperature deviations during shipping can affect potency.
Verify the assay method on the COA. A purity figure from a UV-based HPLC without a reference standard is less reliable than one from a calibrated LC/MS method with a certified reference material.
Supply chain checks:
Direct manufacturer relationships provide lot-level traceability and the ability to request method validation statements.
Consistent lot numbers across repeat orders indicate stable manufacturing rather than opportunistic spot purchasing.
PeptidesFromChina operates as a research-focused sourcing platform with direct relationships with established synthesis facilities, batch consistency verification, and independent purity testing. For procurement teams sourcing research-grade MK-677, that supply chain structure reduces the risk of identity substitution and batch-to-batch variability that are common failure modes in the reseller tier.
Pro Tip: When onboarding a new supplier, request a method validation statement for the HPLC or LC/MS assay used on the COA, and commission a rapid-turnaround third-party LC/MS confirmation on the first batch received. The cost of independent testing is negligible relative to the cost of a failed study caused by an identity or purity issue.
Key Takeaways
The human terminal plasma half-life of MK-677 is approximately 24 hours, supporting once-daily dosing, a five-day plasma washout, and a two-week window for full IGF-1 normalization after cessation.
Point Details Human terminal half-life Approximately 24 hours from steady-state human PK trials; the number that governs dosing and washout math. Once-daily dosing rationale A 24-hour half-life means each dose replaces cleared drug before trough drops below the effective threshold. Plasma washout timeline Five half-lives (~5 days) clears ~97% of plasma drug; IGF-1 normalization may take 1–2 weeks longer. Primary safety signals Fasting glucose rises (~5 mg/dL mean in one 12-month trial), mild edema, and reduced insulin sensitivity from sustained GH elevation. PeptidesFromChina sourcing Batch-verified, independently tested research-grade MK-677 with direct manufacturer traceability for procurement teams.
A researcher’s perspective on what the half-life actually changes
The 24-hour half-life is not just a pharmacology footnote. It determines when to draw blood, how long to run a washout, and whether a subject’s baseline IGF-1 is actually clean. Studies that ignore steady-state onset and collect PK samples on day one or two are measuring single-dose kinetics, not the trough concentrations that define the compound’s sustained biological effect. That methodological gap explains much of the variability in published MK-677 PD data.
The procurement side carries equal weight. A compound with a well-characterized half-life is only useful if the material in the vial is actually MK-677 at the stated purity. The investigational status of this compound means there is no regulatory backstop. Independent LC/MS confirmation on each new batch is not optional for serious research; it is the minimum standard that makes the PK data collected from that batch interpretable.
Useful primary references for MK-677 pharmacokinetics
Researchers looking to go beyond secondary summaries should consult these sources directly:
PubMed 10404019: The primary human PK/PD trial for MK-677 oral administration; contains the PK tables and sampling methodology that underpin the 24-hour half-life estimate.
PMC4121852: A comprehensive review of MK-0677 preclinical and clinical evidence, including animal PK data and GH/IGF-1 trial summaries.
Annals of Internal Medicine / ACP Journals: The 12-month randomized trial in older adults; the most detailed human safety and PD dataset in the open literature.
PubChem CID 9939050: Chemical identifiers, molecular weight, and registry data for procurement and identity verification.
ChEMBL ChEMBL13817: Curated bioactivity records linking MK-677 to GHS-R1a; useful for target annotation and mechanism review.
Halflife-labs MK-677 entry: Concise PK summary with half-life, steady-state, and dosing parameters compiled from trial data.
Peptide Reference MK-677: Secondary corroboration of dosing patterns, half-life, and common PD effects.
BodyHackGuide MK-677: Quick-reference PK and dosing summary; useful for cross-checking half-life and steady-state claims.
Sport Integrity Australia ibutamoren page: Regulatory and anti-doping context, including WADA prohibition status and long biological effect notation.
Research-grade MK-677 sourcing with verified batch documentation
For procurement teams and research labs that need MK-677 with documented batch traceability, PeptidesFromChina provides direct-from-manufacturer access with independent purity verification on each lot. The platform’s supply chain structure bypasses the reseller tier, which is where identity substitution and purity failures most commonly occur in the research peptide market.
Every batch ships with HPLC purity data and mass spectrometry identity confirmation. Procurement teams can request lot-specific COAs before committing to an order. For labs running longevity or metabolic research that extends to related compounds, the same verification standards apply across the catalog, including research-grade epithalon and other longevity peptides.
Submit a sourcing request at peptidesfromchina.co to confirm current stock, minimum order quantities, and batch documentation for MK-677.
This article is for general informational purposes only and does not constitute medical, clinical, or regulatory advice. Confirm current investigational status and applicable regulations with the relevant primary sources or a qualified professional before initiating any research protocol.